H. Lundbeck AS (FRA:LDBA) EPS without NRI: €0.50 (TTM As of Mar. 2026)


FRA:LDBA H. Lundbeck AS FRA:LDBA
81 GF Score
Price €5.93
GF Value €6.31
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is H. Lundbeck AS EPS without NRI?

H. Lundbeck AS FRA:LDBA +3.13% 81 EPS without NRI is €0.50 as of Mar. 2026. GuruFocus rates FRA:LDBA with a GF Score™ of 81/100 and a GF Value™ of €6.31 (Fairly Valued). The stock has 4 warning signs investors should review. Among 787 Drug Manufacturers companies, H. Lundbeck AS ranks better than 61.25% on this metric.

H. Lundbeck AS's earnings per share without non-recurring items for the three months ended in Mar. 2026 was €0.22. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was €0.50.

During the past 12 months, H. Lundbeck AS's average earnings per share (NRI) Growth Rate was 13.40% per year. During the past 3 years, the average earnings per share (NRI) Growth Rate was 16.30% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was -5.40% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for H. Lundbeck AS's EPS without NRI or its related term are showing as below:

FRA:LDBA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -57.1   Med: 6.3   Max: 28.4
Current: 16.3

During the past 13 years, H. Lundbeck AS's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 28.40% per year. The lowest was -57.10% per year. And the median was 6.30% per year.

FRA:LDBA's 3-Year EPS without NRI Growth Rate is ranked better than
61.25% of 787 companies
in the Drug Manufacturers industry
Industry Median: 9.7 vs FRA:LDBA: 16.30

H. Lundbeck AS's EPS (Diluted) for the three months ended in Mar. 2026 was €0.22. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €0.50.

H. Lundbeck AS's EPS (Basic) for the three months ended in Mar. 2026 was €0.22. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was €0.50.


H. Lundbeck AS  (FRA:LDBA) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


H. Lundbeck AS EPS without NRI Related Terms


H. Lundbeck AS EPS without NRI Historical Data

* Premium members only.

The historical data trend for H. Lundbeck AS's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

H. Lundbeck AS EPS without NRI Chart

H. Lundbeck AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.20 0.28 0.31 0.38 0.44

H. Lundbeck AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.15 0.13 0.15 -0.00 0.22

FRA:LDBA vs ZTS, UTHR, VTRS: EPS without NRI Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, H. Lundbeck AS's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


H. Lundbeck AS PE Ratio without NRI vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, H. Lundbeck AS's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where H. Lundbeck AS's PE Ratio without NRI falls into.


FRA:LDBA
81GF Score
H. Lundbeck AS FRA:LDBA
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

H. Lundbeck AS EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of €0.50 mean?
H. Lundbeck AS (FRA:LDBA) has a EPS without NRI of €0.50 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on H. Lundbeck AS and its competitors. According to the industry distribution chart, H. Lundbeck AS ranks #305 out of 787 companies in the Drug Manufacturers industry, placing it in the top 38.8%.
Is H. Lundbeck AS's EPS without NRI too high?
H. Lundbeck AS's current EPS without NRI is €0.50. Based on the distribution chart, H. Lundbeck AS ranks #305 out of 787 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, H. Lundbeck AS has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does H. Lundbeck AS's EPS without NRI compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, H. Lundbeck AS ranks #305 out of 787 companies for EPS without NRI. This puts H. Lundbeck AS in the upper half of its industry. The industry median EPS without NRI is 9.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Drug Manufacturers company?
The median EPS without NRI among Drug Manufacturers companies is 9.70, based on 787 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on H. Lundbeck AS and its competitors. For the Drug Manufacturers industry, the median EPS without NRI is 9.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. H. Lundbeck AS's current EPS without NRI is €0.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is H. Lundbeck AS stock overvalued right now?
Based on GuruFocus' analysis, H. Lundbeck AS (FRA:LDBA) is currently considered Fairly Valued. The stock's GF Value™ is €6.31, compared to a current price of €5.93 — trading 6.1% below its estimated fair value. The current EPS without NRI is €0.50. H. Lundbeck AS's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For H. Lundbeck AS (FRA:LDBA), the current EPS without NRI is €0.50 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is H. Lundbeck AS (FRA:LDBA) Overvalued in 2026?

Based on GuruFocus' analysis, H. Lundbeck AS stock appears to be undervalued. The current stock price of €5.93 is trading 6.1% below its estimated GF Value™ of €6.31. GuruFocus considers H. Lundbeck AS to be Fairly Valued.

Key valuation signals for FRA:LDBA:

  • EPS without NRI: €0.50
  • GF Value™: €6.31 vs. price of €5.93 (6.1% below fair value)
  • GF Score™: 81/100 with 4 warning signs

No single metric tells the full story. See the FRA:LDBA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


H. Lundbeck AS Business Description

Address Ottiliavej 9, Valby, DNK, 2500
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.
81GF Score

Get the complete analysis for FRA:LDBA

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.93
Price
€6.31
GF Value